PVS-10200 increases lumen area in PAD

Pervasis Therapeutics, a US biotechnology firm focused on active cellular therapies, reported strong new preclinical data for PVS-10200,  a minimally-invasive therapy that uses a preparation of  tissue-engineered allogeneic endothelial cells. Results from the study  found that treatment following an intervention for peripheral arterial  disease resulted in a statistically-significant increased lumen area,  reduced intimal area and decreased occlusion compared to control.

In this preclinical study, researchers evaluated treatment with  ultrasound-guided percutaneous administration of PVS-10200 to the  outside of porcine femoral arteries immediately following angioplasty  and stent placement. Animals in the control group received angioplasty  and stents with no further treatment (sham standard-of-care control). A  third group was treated with injection of matrix alone. A total of 36  femoral arteries were evaluated in the study and evaluations were  conducted at 30 and 90 days following treatment. At 90 days,  PVS-10200 treated arteries had significantly decreased intimal area  compared to control (p<0.05) and increased lumen area (p<0.05).